Clinical trial Recruiting at 1 site Interventional Ages 5 to 7

Helping children with developmental language disorder predict upcoming words in sentences

Official title: Sentence Prediction in Developmental Language Disorder

Run by Father Flanagan's Boys' Home · NCT07510854 · Data updated 2026-11-12

This project tries training sentence-prediction skills in school-age children with developmental language disorder to see if it helps them understand sentences better.

Quick facts

Study typeInterventional
Ages5 Years to 7 Years
SexAll
Enrollment80 (estimated)
SponsorFather Flanagan's Boys' Home
Academic / other
Locations1 site (Omaha, Nebraska)
StatusRecruiting
StartedFebruary 16, 2026
Main results expectedJuly 2028
Study endsJuly 2028
Registry record updatedApril 6, 2026
Trial IDNCT07510854 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are school-age children with DLD (TNL-2 score < 92) who have normal hearing and vision, no neurological disorders, non-autistic-range CARS-2 scores, and Visual Spatial Index scores ≥ 75.

Probably not a fit

Children with autism-spectrum disorder, significant visual-spatial cognitive impairment (Visual Spatial Index < 75), uncorrected hearing or vision problems, or those unable to travel to the study site are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-site interventional project compares children with developmental language disorder (DLD) to typically developing peers on tasks that manipulate thematic role cues and sentence complexity to probe prediction during sentence processing. Children complete behavioral tasks that measure how rapidly and accurately they anticipate upcoming words after verbs under different sentence structures. Group membership is determined using the Test of Narrative Language-2 (TNL-2) and participants must meet hearing, vision, and cognitive cutoffs while excluding autism-range scores. Results will focus on whether differences in prediction relate to sentence comprehension and whether manipulating thematic role or complexity changes predictive behavior.

Why it matters

Potential benefit: If successful, the approach could improve sentence comprehension for children with DLD and inform targeted language interventions that boost classroom learning.

How similar studies have gone: Prior work shows prediction supports sentence comprehension in typical development and that children with DLD have reduced predictive ability, but applying targeted manipulations to improve prediction in DLD is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pass a hearing screening at 25dB at 0.5, 1, 2, and 4 kHz
* Have normal or corrected-to-normal vision
* Have no history of neurological disorders
* For DLD group, Test of Narrative Language 2 (TNL-2) score less than 92
* For TD group, TNL-2 score greater than 92, a cut-off that provides excellent sensitivity/specificity (.92/.92).

Exclusion Criteria:

* Scores in the Autism range on the Childhood Autism Rating Scale 2 (CARS-2)
* Scores below 75 on the Visual Spatial Index of the Wechsler Preschool and Primary Scale of Intelligence 4 (WPPSI-IV)

Where it's running

  • Boys Town National Research Hospital
    Omaha, Nebraska, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.